Thank you, Joe, and good morning, everyone. First, I will go over the results for the fourth quarter and then review our revenue and earnings guidance for the first quarter that we provided in the press release issued yesterday.
As Howard mentioned earlier, in February 2013, we sold our clinical trial services business, and accordingly this business has been reclassified as discontinued operations at year-end. The current and historical amounts that I will be reviewing have been adjusted to reflect this.
Revenue from continuing operations in the fourth quarter was $112 million, up 3% from the prior year quarter, due primarily to strong revenue growth in our Physician Staffing segment. Sequentially, revenue was down 0.5% due to a seasonal decline in physician staffing partially offset by revenue growth in the Nurse and Allied and other Human Capital Management segments.
Our consolidated gross profit margin was 25%, down 270 basis points from the prior year, but up 60 basis points from the prior quarter. In the fourth quarter, we took a $750,000 charge for an indemnity claim for professional liability in our Nurse and Allied Staffing segment. We have an offsetting claim with an insurance carrier against this charge, which we believe will allow us to reverse some, if not all of this expense in the future period.
However, under U.S. GAAP, we are precluded from recognizing this gain contingency until it is realized. The sequential profit margin improvement reflected our efforts to expand the bill-pay spread in our Nurse and Allied Staffing business to help offset the margin erosion we experienced since last year from higher housing and health insurance costs.
The year-over-year margin decline was due to the aforementioned professional liability charge in the current quarter, housing and health insurance cost increases as well as a favorable professional liability accrual adjustment in our Physician Staffing business in the prior year quarter.
SG&A for the quarter was $27.1 million, up 3% from the prior year and 1% sequentially. Included in this quarter’s result was a one-time $680,000 expense for correcting a calculation of deferred rent, which primarily accumulated from 2002 to 2010 and which would have had an immaterial impact on rent expense during each of these years. Expenses in the fourth quarter also included approximately $600,000 in equity based compensation expenses, essentially unchanged from prior year and the prior quarter.
The adjusted EBITDA from continuing operations as defined in our press release was $1.3 million, representing 1.2% adjusted EBITDA margin. Interest expense of $433,000 was down 36% from the prior year quarter due to the continued delevering of our balance sheet.
Pretax loss from continuing operations in the fourth quarter was $1.3 million on which we had incurred the income tax expense of $1.7 million. The income tax expense in the fourth quarter included $2.5 million in charges related to our decision to repatriate the accumulated earnings and profits from our India-based subsidiary including dividend withholding taxes. Previously, we planned to keep these earnings and profits offshore indefinitely to support the expansion in India of our now discontinued clinical trial services business.
Net loss from continuing operations was $3 million or $0.10 per diluted share. This compares to net loss from continuing operations in the prior year quarter of $200,000. Net loss from discontinued operations in the fourth quarter was $6.5 million after-tax or $0.21 per diluted share and included a non-cash goodwill impairment charge in the fourth quarter of $0.24 per diluted share.
Including this continued operations we had a net loss in the fourth quarter of $9.5 million or $0.31 per diluted share, in the same quarter a year ago net income including discontinued operations was $0.5 million or $0.02 per diluted share. For the full-year 2012 consolidated revenue from continuing operations was $443 million and compares to $439 million in the prior year. We had a loss from continuing operations of $20.7 million or $0.67 per diluted share.
Including discontinued operations we had a net loss of $42.2 million or $1.37 per diluted share. The net loss included a non-cash goodwill impairment charge in the second quarter of 2012 of $12.1 million after-tax or $0.39 per diluted share related to the Nurse and Allied Staffing business segment. It also included non-cash goodwill and trademark impairment charges in the third and fourth quarter of 2012, totaling $24.2 million after-tax or $0.79 per diluted share related to the discontinued Clinical Trials Services business segment.
In 2011, income from continuing operations was $1.5 million or $0.05 per diluted share and net income including discontinued operations was $4.1 million or $0.13 per diluted share.
Turning to the balance sheet, we ended the quarter with $33.9 million of debt and $10.5 million of cash and cash equivalents. Net of cash, our debt to total capital ratio was 9.6% and the current ratio was 2:1.
Day sales outstanding excluding the discontinued clinical trial services business was 52 days, down 2 days from the prior quarter and unchanged from the prior year.
We generated $4.4 million of cash from operating activities in the fourth quarter compared to $3.7 million in the prior year quarter. Capital expenditures were approximately $100,000 in the fourth quarter and $2.2 million in the full year 2012.
On January 9, 2013 we entered into a new loan agreement with Bank of America for a $65 million asset based revolver facility, which we believe is better suited for our current needs.
On February 15 of 2013, we repaid all $29.3 million of our then outstanding bank debt from the net proceeds of the sale of the clinical trial services business and we currently have more than $25 million of cash.
As a result of the refinancing, we will be writing off in the first quarter of 2013 approximately $1.3 million of debt issuance cost related to our prior facility.
Let me drill down next into our 3 reporting segments. We averaged 2,452 field FTEs in the fourth quarter, essentially flat with both the prior year and the prior quarter. Nurse and Allied Staffing segments revenue in the fourth quarter was $70.9 million, up 1% versus the prior year, and 2% sequentially. Revenue per FTE per day was up 1% from the prior year and 2% sequentially. The average travel nurse bill rate was up 2% both from the prior year and sequentially.
The book-to-bill ratio averaged 99% in the fourth quarter. Segment contribution income as defined in our press release was $4 million in the fourth quarter, down 27% from the prior year, but up 36% sequentially.
The contribution income margin was 5.7% in the fourth quarter, a decrease of 210 basis points year-over-year, but an increase of 140 basis points sequentially. The year-over-year decline was primarily due to the aforementioned professional liability charge as well as higher health insurance claims. The sequential margin improvement was due to a widening of the bill-pay spread and a favorable workers compensation accrual adjustment partially offset by professional liability charge.
For the year as a whole segment revenue was $278 million down slightly from the prior year, while contribution income was $13.2 million, down 41% from the prior year.
Let me turn next to our physician staffing segment. Revenue was $30.7 million in the fourth quarter, up 10% from the prior year, but down 6% sequentially due to seasonal factors. Physician staffing days filled were up slightly from the prior year, but down 10% sequentially. The year-over-year increase in revenue was driven by higher average revenue per days filled due to a combination of higher bill rates and changes in specialty mix, in particular higher volume from the emergency room physicians.
Segment contribution income for the fourth quarter was $2.5 million, down 10% from the prior year, and 21% sequentially. The year-over-year decrease was primarily due to higher professional liability insurance expenses in the current quarter compared to a favorable professional liability insurance accrual adjustment in the prior quarter, partially offset by a lower non-income based state taxes. The sequential decline was due primarily to reduced operating leverage. For the year as a whole, segment revenue was $124 million, up 4% from the prior year, while contribution income was $10.7 million, down 6% from the prior year.
Revenue for the other Human Capital Management Services segment in the fourth quarter was $10.2 million, down 5% from the prior year due to lower seminar attendance in our education and training business partially offset by higher retainer revenue in our search business. On a sequential basis, segment revenue was up 4% with both the education and search businesses contributing to the revenue growth.
The contribution income margin was down 270 basis points year-over-year due primarily to the reduced operating leverage of the education business, but up 500 basis points sequentially with both the education and search businesses contributing to the sequential margin improvement. For the year as a whole segment revenue was $41 million, down 1% from the prior year and contribution income was $1.9 million, down 39% from the prior year.
This brings me to our guidance for the first quarter of 2013. The following statements are based on current management expectations. Such statements are forward-looking and actual results may differ materially. These statements do not include the potential impact of any future mergers, acquisitions or other business combinations, impairment charges or valuation allowances, or any material legal proceedings.
We’ll project the average nurse and allied staffing field FTE count to be in the 2,450 to 2,500 range in the first quarter of 2013. Consolidated revenue for the first quarter is expected to be in the $110 million to $112 million range. With an expected sequential revenue increase in our Nurse and Allied Staffing segment, offset by a decrease in other Human Capital Management Services segment.
We expect our gross profit margin to be in the 24.5% to 25% range, an adjusted EBITDA margin from continuing operation to be in the 0% to 2% range. Interest expense is expected to be approximately $250,000 in the first quarter, also included in our first quarter guidance is the write-off of approximately $1.3 million of debt issuance cost, related to our prior credit facility.
Our effective tax rate in the first quarter is expected to be in excess of 100%. This unusual tax rate is due primarily to the impact of non-deductibility of certain per diem payments, the effect of which is greatly magnified by our relatively low pre-tax book income.
Our cash tax rate for 2013 is expected to be approximately 30%. Based on these assumptions, we expect our earnings per diluted share to be essentially at break even for the first quarter of 2013.
This concludes our formal comments. However, before we open up the lines to answer any questions, I would like to hand the call back over to Joe for some concluding remarks.